Second-line Systemic Treatment for Metastatic Colorectal Cancer: A Systematic Review and Bayesian Network Meta-analysis Based on RCT

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Dec 23

PMID 39715232

Authors

Chengyu Sun

Enguo Fan

Luqiao Huang

Zhengguo Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The optimal second-line systemic treatment for metastatic colorectal cancer (mCRC) is inconclusive.

Methods: We searched PubMed, Web of Science, EMBASE, and Cochrane Library for RCTs comparing second-line systemic treatments for mCRC from the inception of each database up to February 3, 2024. Markov Chain Monte Carlo (MCMC) technique was used in this network meta-analysis (NMA) to generate the direct and indirect comparison results among multiple treatments in progression-free survival (PFS), overall response rate (ORR), overall survival (OS), complete response (CR), partial response (PR), grade 3 and above adverse events (Grade ≥ 3AE), and any adverse events (Any AE). The surface under the cumulative ranking curve (SUCRA) was adopted to evaluate the probability of each treatment being the optimum intervention. Subgroup analyses were performed based on the RAS gene status.

Results: A total of 47 randomized controlled trials were included, involving 16,925 patients and 44 second-line systemic treatments. In improving OS, FOLFOX + Bevacizumab + Erlotinib exhibited significant superiority (SUCRA:92.7%). In improving PFS, Irinotecan + CMAB009 (SUCRA:86.4%) had advantages over other treatments. FOLFIRI + Trebananib (SUCRA:88.1%) had a significant advantage in improving ORR. Among multiple second-line treatments, the SUCRA values of FOLFOX + Bevacizumab in PFS, OS, ORR, and PR were 83.4%, 74.0%, 81.1%, and 86.1%, respectively, and the safety was not significantly different from other interventions. Subgroup analyses showed that FOLFIRI + Bevacizumab + panitumumab ranked among the top in survival outcomes in the RAS-mutant population (OS SUCRA: 87.9%; PFS SUCRA: 70.2%); whereas in the RAS-wild-type population, FOLFIRI + Bevacizumab significantly improved survival outcomes (OS SUCRA: 73.2%; PFS SUCRA: 65.1%).

Conclusion: For most people, FOLFOX + Bevacizumab may be the best second-line systemic treatment regimen for mCRC. For RAS-mutant populations, FOLFIRI + Bevacizumab + Panitumumab is recommended. However, the therapeutic effect may be affected by the patient's physiological state, and clinicians should apply it based on actual conditions.

References

Kanas G, Taylor A, Primrose J, Langeberg W, Kelsh M, Mowat F . Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012; 4:283-301. PMC: 3496330. DOI: 10.2147/CLEP.S34285. View

Bennouna J, Hiret S, Bertaut A, Bouche O, Deplanque G, Borel C . Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA Oncol. 2018; 5(1):83-90. PMC: 6440242. DOI: 10.1001/jamaoncol.2018.4465. View

Cohn A, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah B . A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol. 2013; 24(7):1777-1785. DOI: 10.1093/annonc/mdt057. View

Modest D, Pant S, Sartore-Bianchi A . Treatment sequencing in metastatic colorectal cancer. Eur J Cancer. 2019; 109:70-83. DOI: 10.1016/j.ejca.2018.12.019. View

Chebib R, Verlingue L, Cozic N, Faron M, Burtin P, Boige V . Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. Semin Oncol. 2017; 44(2):114-128. DOI: 10.1053/j.seminoncol.2017.07.004. View

Becouarn Y, Gamelin E, Coudert B, Negrier S, Pierga J, Raoul J . Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol. 2001; 19(22):4195-201. DOI: 10.1200/JCO.2001.19.22.4195. View

Kim G, Sargent D, Mahoney M, Rowland Jr K, Philip P, Mitchell E . Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009; 27(17):2848-54. PMC: 2698019. DOI: 10.1200/JCO.2008.20.4552. View

Mekenkamp L, Koopman M, Teerenstra S, van Krieken J, Mol L, Nagtegaal I . Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer. 2010; 103(2):159-64. PMC: 2906733. DOI: 10.1038/sj.bjc.6605737. View

Peeters M, Price T, Cervantes A, Sobrero A, Ducreux M, Hotko Y . Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28(31):4706-13. DOI: 10.1200/JCO.2009.27.6055. View

10.

Ettrich T, Perkhofer L, Decker T, Hofheinz R, Heinemann V, Hoffmann T . Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). Int J Cancer. 2020; 148(6):1428-1437. DOI: 10.1002/ijc.33296. View

11.

Lenz H, Philip P, Saunders M, Kolevska T, Mukherjee K, Samuel L . Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2017; 80(6):1161-1169. PMC: 6863159. DOI: 10.1007/s00280-017-3438-y. View

12.

Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H . Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). Eur J Cancer. 2020; 135:11-21. DOI: 10.1016/j.ejca.2020.04.014. View

13.

Zhang X, Duan R, Wang Y, Liu X, Zhang W, Zhu X . FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. Ther Adv Med Oncol. 2022; 14:17588359211068737. PMC: 8771434. DOI: 10.1177/17588359211068737. View

14.

Barlow A, Nakas A, Pattenden C, Martin-Ucar A, Dennison A, Berry D . Surgical treatment of combined hepatic and pulmonary colorectal cancer metastases. Eur J Surg Oncol. 2008; 35(3):307-12. DOI: 10.1016/j.ejso.2008.06.012. View

15.

Obermannova R, Van Cutsem E, Yoshino T, Bodoky G, Prausova J, Garcia-Carbonero R . Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 2016; 27(11):2082-2090. PMC: 5091322. DOI: 10.1093/annonc/mdw402. View

16.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

17.

Rothenberg M, Cox J, Butts C, Navarro M, Bang Y, Goel R . Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008; 19(10):1720-6. DOI: 10.1093/annonc/mdn370. View

18.

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T . Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021; 39(4):273-284. PMC: 8078423. DOI: 10.1200/JCO.20.02088. View

19.

Smolenschi C, Perret A, DallArmellina F, Boige V, Malka D, Hollebecque A . An appraisal of emerging second line therapies for metastatic colorectal cancer. Expert Rev Gastroenterol Hepatol. 2020; 15(2):165-179. DOI: 10.1080/17474124.2021.1840975. View

20.

Giantonio B, Catalano P, Meropol N, ODwyer P, Mitchell E, Alberts S . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12):1539-44. DOI: 10.1200/JCO.2006.09.6305. View